TY - JOUR
T1 - Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia
T2 - Open Forum Infectious Diseases
AU - Salton, F.
AU - Confalonieri, P.
AU - Umberto Meduri, G.
AU - Santus, P.
AU - Harari, S.
AU - Scala, R.
AU - Lanini, S.
AU - Vertui, V.
AU - Oggionni, T.
AU - Caminati, A.
AU - Patruno, V.
AU - Tamburrini, M.
AU - Scartabellati, A.
AU - Parati, M.
AU - Villani, M.
AU - Radovanovic, D.
AU - Tomassetti, S.
AU - Ravaglia, C.
AU - Poletti, V.
AU - Vianello, A.
AU - Gaccione, A.T.
AU - Guidelli, L.
AU - Raccanelli, R.
AU - Lucernoni, P.
AU - Lacedonia, D.
AU - Foschino Barbaro, M.P.
AU - Centanni, S.
AU - Mondoni, M.
AU - Davì, M.
AU - Fantin, A.
AU - Cao, X.
AU - Torelli, L.
AU - Zucchetto, A.
AU - Montico, M.
AU - Casarin, A.
AU - Romagnoli, M.
AU - Gasparini, S.
AU - Bonifazi, M.
AU - D’Agaro, P.
AU - Marcello, A.
AU - Licastro, D.
AU - Ruaro, B.
AU - Volpe, M.C.
AU - Umberger, R.
AU - Confalonieri, M.
N1 - Cited By :7
Export Date: 5 March 2021
References: Grasselli, G, Pesenti, A, Cecconi, M., Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response (2020) JAMA, 323, pp. 1545-1546; Bhatraju, PK, Ghassemieh, BJ, Nichols, M, Covid-19 in critically ill patients in the Seattle region—case series (2020) N Engl J Med, 382, pp. 2012-2022; Confalonieri, M, Gorini, M, Ambrosino, N, Respiratory intensive care units in Italy: a national census and prospective cohort study (2001) Thorax, 56, pp. 373-378. , Scientific Group on Respiratory Intensive Care of the Italian Association of Hospital Pneumonologists; Vitacca, M, Nava, S, Santus, P, Harari, S., Early consensus management for non-ICU acute respiratory failure SARS-CoV-2 emergency in Italy: from ward to trenches (2020) Eur Respir J, 55, p. 2000632; Giamarellos-Bourboulis, EJ, Netea, MG, Rovina, N, Complex immune dysregulation in COVID-19 patients with severe respiratory failure (2020) Cell Host Microbe, 27, pp. 992-1000. , e3; Villar, J, Confalonieri, M, Pastores, SM, Meduri, GU., Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019 (2020) Crit Care Explor, 2, p. e0111; Schoenfeld, DA, Bernard, GR, Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome (2002) Crit Care Med, 30, pp. 1772-1777. , ARDS Network; Ranieri, VM, Rubenfeld, GD, Thompson, BT, Acute respiratory distress syndrome: the Berlin definition (2012) JAMA, 307, pp. 2526-2533; Nicastri, E, Petrosillo, N, Ascoli Bartoli, T, National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management (2020) Infect Dis Rep, 12, p. 8543; Vincent, JL, de Mendonça, A, Cantraine, F, Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine (1998) Crit Care Med, 26, pp. 1793-1800; Fang, X, Mei, Q, Yang, T, Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 (2020) J Infect, 81, pp. 147-178; von Elm, E, Altman, DG, Egger, M, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies (2007) Lancet, 370, pp. 1453-1457. , STROBE Initiative; Henry, BM, de Oliveira, MHS, Benoit, S, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis (2020) Clin Chem Lab Med, 58, pp. 1021-1028; Meduri, GU, Chrousos, GP., General adaptation in critical illness: glucocorticoid receptor-alpha master regulator of homeostatic corrections (2020) Front Endocrinol (Lausanne), 11, p. 161; Vichyanond, P, Irvin, CG, Larsen, GL, Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone (1989) J Allergy Clin Immunol, 84, pp. 867-873; Horby, P, Lim, WS, Emberson, JR, Dexamethasone in hospitalized patients with Covid-19 - preliminary report [published online ahead of print July 17, 2020] (2020) N Engl J Med, , RECOVERY Collaborative Group; Meduri, GU, Bridges, L, Shih, MC, Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature (2016) Intensive Care Med, 42, pp. 829-840; Confalonieri, M, Urbino, R, Potena, A, Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study (2005) Am J Respir Crit Care Med, 171, pp. 242-248; Long, Y, Xu, Y, Wang, B, Clinical recommendations from an observational study on MERS: glucocorticoids was benefit in treating SARS patients (2016) Int J Clin Exp Med, 9, pp. 8865-8873; Chen, RC, Tang, XP, Tan, SY, Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience (2006) Chest, 129, pp. 1441-1452; Yin-Chun Yam, L, Chun-Wing Lau, A, Yuk-Lin Lai, F, Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong (2007) J Infect, 54, pp. 28-39; Li, H, Yang, SG, Gu, L, Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia (2017) Influenza Other Respir Viruses, 11, pp. 345-354. , National Influenza A(H1N1)pdm09 Clinical Investigation Group of China; Draghici, S, Nguyen, T-M, Sonna, LA, COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve out- come in severe cases [Preprint] (2020) Research Square, , 15 May; Czock, D, Keller, F, Rasche, FM, Häussler, U., Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids (2005) Clin Pharmacokinet, 44, pp. 61-98; Wölfel, R, Corman, VM, Guggemos, W., Virological assessment of hospitalized patients with COVID-2019 (2020) Nature, 581, pp. 465-469; Jung, J, Oh, DK, Ahn, JH, Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 (2020) J Infect, 81, pp. e79-e81; Arabi, YM, Mandourah, Y, Al-Hameed, F, Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome (2018) Am J Respir Crit Care Med, 197, pp. 757-767. , Saudi Critical Care Trial Group; Mehta, P, McAuley, DF, Brown, M, COVID-19: consider cytokine storm syndromes and immunosuppression (2020) Lancet, 395, pp. 1033-1034. , HLH Across Speciality Collaboration, UK
PY - 2020
Y1 - 2020
N2 - Background. In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality. Methods. We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels. Results. Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24–0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12–0.73) and more days off invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the 2 groups (P = .84). Conclusion. In patients with severe COVID-19 pneumonia, early administration of prolonged, low dose MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. © The Author(s) 2020.
AB - Background. In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality. Methods. We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels. Results. Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24–0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12–0.73) and more days off invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the 2 groups (P = .84). Conclusion. In patients with severe COVID-19 pneumonia, early administration of prolonged, low dose MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. © The Author(s) 2020.
KW - ARDS
KW - COVID-19
KW - Methylprednisolone
KW - Pneumonia
KW - SARS-cov-2
U2 - 10.1093/ofid/ofaa421
DO - 10.1093/ofid/ofaa421
M3 - Article
VL - 7
JO - Open Forum Infect. Dis.
JF - Open Forum Infect. Dis.
SN - 2328-8957
IS - 10
ER -